Moxifloxacin Noridem Enterprises (Moxifloxacin)

Moxifloxacin is indicated for several serious bacterial infections affecting the respiratory, skin and intra‑abdominal systems.

• Community‑acquired bacterial pneumonia: improves clinical cure rates and reduces mortality in adult patients.
• Acute bacterial sinusitis: eradicates the causative pathogens and relieves sinus inflammation.
• Acute bacterial exacerbation of chronic bronchitis: shortens symptom duration and prevents disease progression.
• Skin and skin structure infections: achieves bacterial clearance in complicated cellulitis and wound infections.
• Complicated intra‑abdominal infections: provides broad‑spectrum coverage for mixed aerobic and anaerobic organisms.

• Moxifloxacin exerts its antibacterial activity by binding to the bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase IV. Inhibition of these enzymes prevents the supercoiling and separation of bacterial DNA required for replication and transcription, leading to rapid bactericidal effect against a wide range of Gram‑positive and Gram‑negative organisms. The drug penetrates well into respiratory tissues, sinus mucosa, skin, and peritoneal fluid, achieving concentrations above the minimum inhibitory concentrations for susceptible pathogens.

Moxifloxacin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: loose stools, usually self‑limiting.
• Headache: transient cranial discomfort.
• Dizziness: occasional vertigo or light‑headedness.
• Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects

• Tendon rupture: especially Achilles tendon, may occur without warning.
• QT interval prolongation: can precipitate cardiac arrhythmias.
• Severe hypersensitivity reactions: including Stevens‑Johnson syndrome.
• Clostridioides difficile colitis: antibiotic‑associated severe diarrhea.
• Hepatotoxicity: elevated liver enzymes or jaundice.

When using intravenous moxifloxacin, clinicians should observe several safety considerations to minimize risk.

• Renal impairment: monitor renal function and adjust therapy as needed.
• Hepatic impairment: use with caution in patients with liver disease.
• QT prolongation risk: obtain baseline ECG and avoid in patients with known cardiac arrhythmias.
• Concomitant corticosteroid therapy: increased risk of tendon rupture; assess benefit‑risk.
• Known hypersensitivity to fluoroquinolones: contraindicated; discontinue immediately if reaction occurs.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Moxifloxacin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Antacids containing magnesium or aluminum: markedly reduce moxifloxacin absorption.
• Warfarin: may potentiate anticoagulant effect and increase bleeding risk.
• Co‑administration with other fluoroquinolones: additive toxicity without therapeutic benefit.

Moderate Interactions (Monitor Closely)

• Cyclosporine: may increase cyclosporine serum concentrations.
• Oral hypoglycemic agents: can cause dysglycemia; monitor blood glucose.
• Corticosteroids: combined use raises risk of tendon rupture.